|
|
Fabiola Terzi, Martine Burtin, Mehrak Hekmati, Pierre Federici, Giselle Grimber, Pascale Briand, Gérard Friedlander
J Clin Invest. 2000;
106(2):225
doi:10.1172/JCI8315
Abstract |
Full text
| PDF

T
he role of EGF in the evolution of renal lesions after injury is still controversial. To determine whether the EGF expression is beneficial or detrimental, we generated transgenic mice expressing a COOH-terminal–truncated EGF-R under the control of the kidney-specific type 1 γ-glutamyl transpeptidase promoter. As expected, the transgene was expressed exclusively at the basolateral membrane of proximal tubular cells. Under basal conditions, transgenic mice showed normal renal morphology and function. Infusion of EGF to transgenic animals revealed that the mutant receptor behaved in a dominant-negative manner and prevented EGF-signaled EGF-R autophosphorylation. We next evaluated the impact of transgene expression on the development of renal lesions in two models of renal injury. After 75% reduction of renal mass, tubular dilations were less severe in transgenic mice than in wild-type animals. After prolonged renal ischemia, tubular atrophy and interstitial fibrosis were reduced in transgenic mice as compared with wild-type mice. The beneficial effect of the transgene included a reduction of tubular cell proliferation, interstitial collagen accumulation, and mononuclear cell infiltration. In conclusion, functional inactivation of the EGF-R in renal proximal tubular cells reduced tubulo-interstitial lesions after renal injury. These data suggest that blocking the EGF pathway may be a therapeutic strategy to reduce the progression of chronic renal failure.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
In search of early events in the development of chronic kidney disease: the emerging role for lipocalin-2/NGAL
T. Rauen, R. Weiskirchen, J. Floege |
Neprol Dial Transplant |
2011 |
.
|
Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease
Adriana S Dusso, Masanori Tokumoto |
Kidney Int |
2011 |
.
|
A conceptual framework for the molecular pathogenesis of progressive kidney disease
H. William Schnaper, Susan C. Hubchak, Constance E. Runyan, James A. Browne, Gal Finer, Xiaoying Liu, Tomoko Hayashida |
Pediatr Nephrol |
2010 |
.
|
Lipocalin 2 is essential for chronic kidney disease progression in mice and humans
Amandine Viau, Khalil El Karoui, Denise Laouari, Martine Burtin, Clément Nguyen, Kiyoshi Mori, Evangéline Pillebout, Thorsten Berger, Tak Wah Mak, Bertrand Knebelmann, Gérard Friedlander, Jonathan Barasch, Fabiola Terzi |
Journal Clinical Investigation |
2010 |
.
|
Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality
Adriana Dusso, Maria Vittoria Arcidiacono, Jing Yang, Masanori Tokumoto |
J STEROID BIOCHEM MOLEC BIOL |
2010 |
.
|
Tubular toxicity of proteinuria
Richard J. Baines, Nigel J. Brunskill |
Nat Rev Nephrol |
2010 |
.
|
New aspects of rapid aldosterone signaling
C. Grossmann, M. Gekle |
Mol Cellular Endocrinol |
2009 |
.
|
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?
Michael Gekle, Claudia Grossmann |
Pfluegers Archiv |
2008 |
.
|
Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors?
Claudia Grossmann, Michael Gekle |
Mol Cellular Endocrinol |
2007 |
.
|
Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells
Y J Lee, Y J Lee, H J Han |
Kidney Int |
2007 |
.
|
Upregulation of ADAM19 in Chronic Allograft Nephropathy.
W. B. W. H. Melenhorst, M. C. van den Heuvel, C. A. Stegeman, J. van der Leij, S. Huitema, A. van den Berg, H. van Goor |
Am J Transplant |
2006 |
.
|
Epidermal growth factor potentiates renal cell death in hydronephrotic neonatal mice, but cell survival in rats
SUSAN C KILEY, BARBARA A THORNHILL, BRIAN C BELYEA, KAREN NEALE, MICHAEL S FORBES, NOREEN C LUETTEKE, DAVID C LEE, ROBERT L CHEVALIER |
Kidney Int |
2005 |
.
|
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach
Alexandre Lautrette, Shunqiang Li, Rohia Alili, Susan W Sunnarborg, Martine Burtin, David C Lee, Gérard Friedlander, Fabiola Terzi |
Nat Med |
2005 |
.
|
EGF-related growth factors in the pathogenesis of murine ARPKD1
Katherine MacRae Dell, Raghad Nemo, William E. Sweeney, Ellis D. Avner |
Kidney Int |
2004 |
.
|
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats
Takeshi Kanda, Shu Wakino, Koichi Hayashi, Koichiro Homma, Yuri Ozawa, Takao Saruta |
Kidney Int |
2003 |
.
|
ECM homeostasis in renal diseases: a genomic approach
M Eikmans, JJ Baelde, E de Heer, JA Bruijn |
J Pathol |
2003 |
.
|
Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability
William E. Sweeney, Kiyoshi Hamahira, Jennifer Sweeney, Michelle Garcia-Gatrell, Philip Frost, Ellis D. Avner |
Kidney Int |
2003 |
.
|
EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats
Vicente E. Torres, William E. Sweeney, Xiaofang Wang, Qi Qian, Peter C. Harris, Philip Frost, Ellis D. Avner |
Kidney Int |
2003 |
.
|
JunD protects against chronic kidney disease by regulating paracrine mitogens
Evangéline Pillebout, Jonathan B. Weitzman, Martine Burtin, Carla Martino, Pierre Federici, Moshe Yaniv, Gérard Friedlander, Fabiola Terzi |
Journal Clinical Investigation |
2003 |
.
|
Enyu Imai, Yoshitaka Isaka |
Curr Opin Nephrol Hypertens |
2002 |
.
|
|
|
|